Male Breast Cancer

These findings support broader access to genetic testing as part of personalized breast cancer risk assessment. ClinicalTrials.gov Identifier: NCT02620852.

P1, N=16, Completed, Providence Health & Services | Active, not recruiting --> Completed

The findings of this study have shown high expression in cases of MBC which are triple negative and negative PR status. This indicates that high Ki67 expression in MBC may be used in stratification of male patients with BC based on disease aggressiveness.

The prognostic value of RS in MBC appears evident; however, sex-specific thresholds may be necessary to optimize treatment stratification. Given current data limitations, male-inclusive clinical trials are needed to elucidate the predictive value of RS in men and improve personalized treatment strategies.

Immunohistochemical staining showed that the tumor cells were positive for BerEp4, GATA-3, AE1/AE3, CAM5.2, ER (70%), AR (10%), PR (10%), and ki67 (10%). In our experience, effusion cytology remains an accurate tool for the diagnosis of metastatic carcinomas.

Therefore, the patient was prescribed adjuvant hormone therapy with tamoxifen...This often leads to more radical surgery for this low-grade neoplasm. Before choosing the extent of surgery, it is necessary to consider the primary size of the tumor along with an intraoperative assessment of the resection margins.

Treatment consisted of neoadjuvant chemotherapy (epirubicin + carboplatin + trastuzumab + pertuzumab), a modified radical mastectomy with latissimus dorsi flap reconstruction and a thoracoscopic lung wedge resection. The therapeutic approach resulted in partial remission of the breast cancer prior to surgery and a stable disease status in the lung, with no recurrence at the 1-year follow-up. This case underscores the importance of comprehensive, integrative strategies and long-term follow-up for managing rare, complex cancer cases.

P=N/A, N=29, Not yet recruiting, The First Medical Center of Chinese PLA General Hospital; The First Medical Center of Chinese PLA General Hospital

This is the first report of genetic profiling of MBC with BM and excellent SRS outcomes. The receptor status and genetic alterations across our patients with MBC BM suggest heterogeneity in disease. Larger studies are needed to further explore MBC BM characteristics and treatment outcomes.

To date, no signs of recurrence have been observed. CONCLUSIONS This report describes a rare case of advanced male breast cancer and a successful outcome following postoperative treatment that included abemaciclib.

Male breast cancer remains rare but demonstrates distinct clinical patterns. While management strategies are largely extrapolated from female breast cancer, understanding specific male-associated risk factors and disease characteristics is crucial. Early detection and targeted therapies tailored to male patients may improve outcomes.

Adjuvant radiotherapy and tamoxifen confer clear survival advantages. The lack of male-specific clinical trials remains a major limitation in optimizing evidence-based care for MBC.